CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Sign Up to like & getrecommendations! Published in 2024 at "Nature"
DOI: 10.1038/s41586-024-07943-7
Abstract: For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities,… read more here.
Keywords: resistance; dual icb; blockade; keap1 stk11 ... See more keywords
Abstract CT084: Relationship betweenSTK11andKEAP1mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct084
Abstract: Background:STK11 (also known as LKB1) and KEAP1 mutations have been associated with chemoresistance and poor outcomes and shown to be more frequent in PD-L1-negative tumors with high tumor mutational burden (TMB). We performed an exploratory… read more here.
Keywords: keap1 status; efficacy; keynote 042; stk11 keap1 ... See more keywords
Abstract LB014: Targeting Stearoyl-coA desaturase (SCD) as a therapeutic strategy in STK11/KEAP1 co-mutant non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb014
Abstract: Introduction: Non-small cell lung cancer (NSCLC) is a highly prevalent subtype of lung cancer. Recent findings in the field have improved the clinical outcomes for only a subset of patients who are responsive to immunotherapy… read more here.
Keywords: cell; keap1; keap1 mutant; stk11 keap1 ... See more keywords
Abstract A111: An evaluation of the classification and reporting of STK11 and KEAP1 variants in a real-world US database of metastatic NSCLC tumours
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Immunology Research"
DOI: 10.1158/2326-6074.io2025-a111
Abstract: Introduction: Inactivating mutations in the STK11 (LKB1) and KEAP1 genes have been associated with poor prognosis in non-small cell lung cancer (NSCLC) patients. Currently, there are no approved treatment options aligned to STK11 and KEAP1;… read more here.
Keywords: classification; variant classification; stk11 keap1; real world ... See more keywords
Association of a STK11/KEAP1-mutation gene expression signature in lung adenocarcinoma with immune desertion in squamous cell carcinomas and mediation by NFE2L2 deregulation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3082
Abstract: 3082Background: KEAP1 and STK11 mutations are associated with resistance to immune checkpoint inhibition (ICI) in non-small cell lung cancer (NSCLC). Mechanisms are currently unknown. Methods: We e... read more here.
Keywords: mutation gene; association stk11; stk11 keap1; cell ... See more keywords
Outcomes in STK11-, KEAP1-, and KRAS-mutant lung squamous cell carcinoma (LSCC) with use of immune checkpoint inhibitors (ICIs).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e20504
Abstract: e20504 Background: Studies have suggested that STK11, KEAP1, and KRAS mutations impact response to ICIs in individuals with lung adenocarcinoma. The effect of these mutations in LSCC is unknown. Methods: We conducted a retrospective analysis… read more here.
Keywords: response; stk11 keap1; keap1 kras; kras mutant ... See more keywords
STK11/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy
Sign Up to like & getrecommendations! Published in 2025 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-2025-305
Abstract: Background The impact of STK11/KEAP1 co-mutations on the efficacy of immunotherapy in patients with SMARCA4-mutant advanced non-small cell lung cancer (NSCLC) remains incompletely understood. Our aim was to investigate the effects of STK11/KEAP1 co-mutations on… read more here.
Keywords: mpfs1 months; keap1 mutations; stk11 keap1; smarca4 mutant ... See more keywords
Concurrent Mutations in STK11 and KEAP1 Cause Treatment Resistance in KRAS Wild-type Non-small-cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Internal medicine"
DOI: 10.2169/internalmedicine.1110-22
Abstract: We herein report a patient with KRAS wild-type non-small-cell lung cancer (NSCLC) with concurrent STK11 and KEAP1 mutations. A 53-year-old man visited a local doctor with a complaint of left shoulder swelling and pain. He… read more here.
Keywords: kras wild; stk11 keap1; resistance; wild type ... See more keywords
TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1357583
Abstract: Background Recently, we could show that the co-mutations of KRAS + KEAP1, STK11 + KEAP1 and KRAS + STK11 + KEAP1 lead to a significantly shorter median overall survival (mOS) in patients with lung cancer… read more here.
Keywords: tp53 mutations; lung adenocarcinoma; stk11 keap1; comparative bioinformatic ... See more keywords
Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1459737
Abstract: Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination with platinum-based chemotherapy (CTx). However, approximately 20–30%… read more here.
Keywords: keap1 mutations; perspectives value; stk11 keap1; keap1 ... See more keywords